Rockville company’s drug to be tested in U.S.

Synthetic Biologics Inc., of Rockville, which develops and commercializes medicines derived from synthetic biology, said its Swedish sublicensee, Meda AB, received approval from U.S. regulators to conduct a Phase II study of a new drug being developed for the treatment of fibromyalgia.